AJCC	American Joint Committee on Cancer
ALND	Axillary lymph node dissection
AR	Androgen receptor
AUC	Area under the curve
CA153	Carbohydrate antigen 15-3
CAFs	Cancer-associated fibroblasts
CEA	Carcinoembryonic antigen
CI	Confidence interval
cN	Clinical nodal stage
DCA	Decision curve analysis
DCs	Dendritic cells
DFS	Disease-free survival
ECM	Extracellular matrix
ECs	Endothelial cells
ER	Estrogen receptor
HDI	Human development index
Her2	Human epidermal growth factor receptor-2
HR	Hormone receptor
IDC	Invasive ductal carcinoma
IDI	Integrated discrimination improvement
IHC	Immunohistochemistry
IIBs	Immune-inflammatory biomarkers
ISH	In situ hybridization
ITC	Isolated tumor cells
MP	Miller–Payne
NAC	Neoadjuvant chemotherapy
NK cells	Natural killer cells
NLR	Neutrophil-to-lymphocyte ratio
NRI	Net reclassification improvement
OR	Odds ratio
OS	Overall survival
pCR	Pathologic complete response
PIV	Pan-immune inflammation value
PLR	Platelet-to-lymphocyte ratio
PR	Progesterone receptor
RCB	Residual cancer burden
RECIST	Response Evaluation Criteria in Solid Tumors
ROC	Receiver operating characteristic
SII	Systemic immune inflammation index
SIRI	Systemic inflammation response index
SLNB	Sentinel lymph node biopsy
TME	Tumor microenvironment
TNBC	Triple-negative breast cancer
ypN	Post-neoadjuvant pathological nodal staging